Pre-made Palivizumab benchmark antibody ( Whole mAb, anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Palivizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.
| Products Name (INN Index) | Pre-Made Palivizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody |
|---|---|
| INN Name | Palivizumab |
| Target | RSV gpF |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | 2hwz:HL |
| 95-98% SI Structure | None |
| Year Proposed | 1998 |
| Year Recommended | 1999 |
| Companies | MedImmune |
| Conditions Approved | Respiratory syncytial virus infections |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | GS Gene Expression System |
| Previous Name | NA |
| Gm Offical Target Name | RSV gpF |
| Package |
